English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Plus monthly

Global: Zendy Tools annual

Global: Zendy Tools monthly

Global: Zendy Free Plan

AIM: To investigate the predictability of interleukin-28B single nucleotidepolymorphism rs12979860 with respect to sustained virological response (SVR) inchronically hepatitis C virus (HCV) genotype-1 patients treated with aprotease-inhibitor and pegylated interferon-$\alpha$ (Peg-INF-$\alpha$) basedtriple-therapy.  METHODS: We searched PubMed, the Cochrane Library and Web of Knowledge forstudies regarding the interleukin 28B (IL-28B)-genotype and protease-inhibitorbased triple-therapy. Ten studies with 2707 patients were included into thismeta-analysis. We used regression methods in order to investigate determinantsof SVR.  RESULTS: IL-28B-CC-genotype patients achieved higher SVR rates (odds 5.34,CI: 3.81-7.49) than IL-28B-non-CC-genotype patients (1.88, CI: 1.43-2.48)receiving triple-therapy. The line of therapy (treatment-na\"ive or-experienced for Peg-INF-$\alpha$) did not affect the predictive value ofIL-28B (p=0.1). IL-28B-CC-genotype patients treated with proteaseinhibitor-based triple-therapy consisting of Boceprevir, Simeprevir, Telapreviror Vaniprevir showed odds of 1.86, 9.77, 4.51 and 0.89, respectively. The oddsfor CC genotype patients treated with Faldaprevir cannot be quantified, as onlya single study with a 100% SVR rate was available.  CONCLUSION: IL-28B-SNP predicts the outcome for chronic HCV genotype-1patients receiving protease inhibitor-based triple-therapy. The predictivevalue varies between the different protease inhibitors.

Predictability of IL-28B-polymorphism on protease-inhibitor-based triple-therapy in chronic HCV-genotype-1 patients: A meta-analysis